Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management

被引:11
|
作者
Karavanaki, Kyriaki [1 ]
Paschou, Stavroula A. [2 ,3 ]
Tentolouris, Nicholas [4 ]
Karachaliou, Foteini [5 ]
Soldatou, Alexandra [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, P&A Kyriakou Childrens Hosp, Dept Pediat 2, Diabet & Obes Unit, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Endocrine Unit, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Diabet Ctr, Dept Clin Therapeut, Alexandra Hosp,Sch Med, Athens, Greece
[4] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Med Sch, Diabet Ctr,Dept Internal Med 1, Athens, Greece
[5] Natl & Kapodistrian Univ Athens, Attikon Gen Hosp, Dept Pediat 3, Diabet & Endocrine Clin, Athens, Greece
关键词
Type 2 diabetes mellitus; Pediatric; Children; Adolescent; Treatment; IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; MELLITUS TYPE-2; DOUBLE-BLIND; YOUTH; PREVALENCE; OBESITY; COMPLICATIONS; SEARCH; SAFETY;
D O I
10.1007/s12020-022-03172-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose Since the dramatic rise of obesity prevalence in childhood and adolescence has contributed to increased rates of type 2 diabetes (T2D) in youth, we sought to explore current evidence-based management options for pediatric T2D patients. Methods A comprehensive literature search was performed for studies of T2D in childhood and adolescence until September 2021. Results Special pathophysiological and diagnostic characteristics of T2D in this age are presented, while the main focus of the article is on management. Lifestyle interventions with healthy diet and exercise are of great importance for the treatment of T2D in children and adolescents. Metformin and insulin remain the traditional therapeutical means, while liraglutide recently gained indication for children older than 10 years both in USA and Europe. Data on the use, efficacy, safety and therapeutic considerations of other pharmacological treatments in children and adolescents with T2D are critically discussed. Conclusion Although many new and promising therapeutic strategies have been introduced during recent years for the management of T2D in adults, available therapeutic options for the management of pediatric T2D remain limited.
引用
收藏
页码:280 / 295
页数:16
相关论文
共 50 条
  • [41] Type 2 diabetes in children and adolescents
    Rosenbloom, Arlen L.
    Silverstein, Janet H.
    Amemiya, Shin
    Zeitler, Phil
    Klingensmith, Georgeanna J.
    PEDIATRIC DIABETES, 2009, 10 : 17 - 32
  • [42] Type 2 diabetes in children and adolescents
    Rosenbloom, A
    Arslanian, S
    Brink, S
    Conschafter, K
    Jones, KL
    Klingensmith, G
    Neufeld, N
    White, N
    PEDIATRICS, 2000, 105 (03) : 671 - 680
  • [43] Type 2 diabetes in children and adolescents
    Amed, Shazhan
    Daneman, Denis
    Mahmud, Farid H.
    Hamilton, Jill
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (03) : 393 - 406
  • [44] Type 2 diabetes in children and adolescents
    Rosenbloom, A
    Arslanian, S
    Brink, S
    Conschafter, K
    Jones, KL
    Klingensmith, G
    Neufeld, N
    White, N
    Fagot-Campagna, A
    Gahagan, S
    Linder, B
    DIABETES CARE, 2000, 23 (03) : 381 - 389
  • [45] Type 2 Diabetes in Children and Adolescents
    Panagiotopoulos, Constadina
    Hadjiyannakis, Stasia
    Henderson, Melanie
    CANADIAN JOURNAL OF DIABETES, 2018, 42 : S247 - S254
  • [46] Type 2 diabetes in children and adolescents
    Weigensberg, Marc J.
    Goran, Michael I.
    LANCET, 2009, 373 (9677): : 1743 - 1744
  • [47] Type 2 diabetes in children and adolescents
    Newmark, Chayim Y.
    Anhalt, Henry
    PEDIATRIC ANNALS, 2007, 36 (02): : 109 - 113
  • [48] An Expert Opinion on the Management of Type 2 Diabetes Mellitus in Children and Adolescents
    Rajput, Rajesh
    Jha, Sujeet
    Panda, Jayanta Kumar
    Subrahmanyam, Appalavenkata Kandregula
    Das, Sambit
    JOURNAL OF DIABETOLOGY, 2021, 12 (04) : 424 - 433
  • [49] Evidence-Based Management of Diabetes in Older Adults
    Arshag D. Mooradian
    Drugs & Aging, 2018, 35 : 1065 - 1078
  • [50] Evidence-Based Cardiovascular Risk Management in Diabetes
    Arshag D. Mooradian
    American Journal of Cardiovascular Drugs, 2019, 19 : 439 - 448